Korro Bio (KRRO) investor relations material

Vision and strategy

• Focus on developing transformative genetic medicines for both rare and highly prevalent diseases.

• Utilizes RNA editing to activate biological pathways without permanent DNA modification.

• Employs modular delivery platforms to target multiple cell types and leverages genetic insights for predictable outcomes.

Technology and approach

• OPERA platform integrates ADAR biology, machine learning, and chemistry for efficient RNA editing and drug design.

• RNA editing enables correction of pathogenic variants and creation of protein variants for disease modulation.

• Programs focus on both protein repair (e.g., AATD, Parkinson's) and pathway activation (e.g., hyperammonemia, ALS).

Pipeline and milestones

• KRRO-121 targets hyperammonemia with a regulatory filing anticipated in H2 2026.

• Development candidates for GalNAc-conjugated AATD and a third liver asset expected in 2026.

• Cash runway extends into H2 2028, supported by $157M post-PIPE financing.